• 1. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

Introduction to Quinuclidine-4-carboxylic acid methyl ester; hydrochloride (CAS No. 102872-28-6)

Quinuclidine-4-carboxylic acid methyl ester; hydrochloride, identified by the chemical compound code CAS No. 102872-28-6, is a significant intermediate in the field of pharmaceutical chemistry. This compound, characterized by its hydrochloride salt form, has garnered considerable attention due to its structural uniqueness and versatile applications in drug development. The quinuclidine scaffold, a seven-membered nitrogen-containing heterocycle, forms the core of this molecule, contributing to its distinct pharmacological properties.

The methyl ester functionality at the 4-position of the quinuclidine ring enhances the compound's reactivity, making it a valuable precursor in synthetic organic chemistry. Furthermore, the presence of a hydrochloride salt indicates its solubility characteristics, which are crucial for formulation development in medicinal applications. This solubility profile facilitates its use in various biological assays and in vitro studies, underscoring its importance in early-stage drug discovery.

In recent years, Quinuclidine-4-carboxylic acid methyl ester; hydrochloride has been extensively explored for its potential in developing novel therapeutic agents. Its structural motif is reminiscent of several bioactive natural products and pharmacologically relevant compounds, suggesting a broad spectrum of biological activities. Researchers have been particularly interested in leveraging this scaffold to design molecules with improved pharmacokinetic profiles and reduced side effects.

One of the most compelling areas of research involving Quinuclidine-4-carboxylic acid methyl ester; hydrochloride is its application as a key intermediate in the synthesis of kinase inhibitors. Kinases are enzymes that play pivotal roles in cell signaling pathways, and their dysregulation is implicated in numerous diseases, including cancer. By modifying the quinuclidine core, scientists have been able to generate compounds that selectively inhibit specific kinases, thereby offering promising candidates for targeted cancer therapies.

Moreover, the hydrochloride form of this compound enhances its stability and bioavailability, making it an attractive candidate for further development. Studies have demonstrated that derivatives of quinuclidine can exhibit potent antiviral and anti-inflammatory properties. For instance, modifications at the 4-position have been shown to modulate the binding affinity of these compounds to their target proteins, leading to improved therapeutic efficacy.

The pharmaceutical industry has also explored Quinuclidine-4-carboxylic acid methyl ester; hydrochloride as a building block for central nervous system (CNS) drugs. The unique spatial arrangement of atoms within the quinuclidine ring allows for optimal interaction with neurotransmitter receptors, making it a suitable scaffold for developing novel psychotropic agents. Preclinical studies have indicated that certain derivatives exhibit anxiolytic and antidepressant effects without significant side effects commonly associated with traditional CNS medications.

Recent advancements in computational chemistry have further accelerated the exploration of Quinuclidine-4-carboxylic acid methyl ester; hydrochloride derivatives. Molecular modeling techniques have enabled researchers to predict the binding modes of these compounds with high accuracy, facilitating rational drug design. This approach has led to the identification of novel analogs with enhanced potency and selectivity against disease-causing targets.

The synthetic methodologies for preparing Quinuclidine-4-carboxylic acid methyl ester; hydrochloride have also seen significant refinements. Modern synthetic strategies leverage transition metal catalysis and asymmetric synthesis to achieve high yields and enantioselectivity. These advancements not only improve the efficiency of producing this compound but also open up new avenues for generating structurally diverse derivatives with tailored biological activities.

In conclusion, Quinuclidine-4-carboxylic acid methyl ester; hydrochloride (CAS No. 102872-28-6) represents a cornerstone in modern pharmaceutical research. Its unique structural features and versatile reactivity make it an indispensable tool for drug discovery and development. As scientific understanding continues to evolve, it is anticipated that this compound will play an even more pivotal role in addressing unmet medical needs across various therapeutic areas.

• 1690-75-1(methyl 1-methylpiperidine-4-carboxylate)
• 1206228-66-1(Methyl 4-ethylpiperidine-4-carboxylate)
• 52632-33-4( )
• 775538-49-3(6-Isoquinolinecarboxylicacid, decahydro-2-methyl-, methyl ester, (4aR,6R,8aS)-rel-)
• 802010-81-7(5-Isoquinolinecarboxylicacid, 2-ethyldecahydro-, methyl ester)
• 99065-42-6(Methyl 1-ethylpiperidine-4-carboxylate)
• 51069-26-2(Methyl quinuclidine-4-carboxylate)
• 892493-16-2(methyl 4-methylpiperidine-4-carboxylate)
• 24252-37-7(Ethyl 1-methylpiperidine-4-carboxylate)
• 51023-67-7(Piperidinium, 4-(methoxycarbonyl)-1,1-dimethyl-, iodide)